New York, USA - November 6, 2024 - Creative Biolabs invites all ADC enthusiasts, from new entrants to seasoned experts, to explore its comprehensive suite of ADC solutions and experience the latest in antibody-drug conjugate (ADC) innovation at Booth #313.
"2023 has been a monumental year for ADC discovery in oncology, represented by the highly anticipated approval of the ninth ADC and a groundbreaking treatment for platinum-resistant ovarian cancer," a scientist at Creative Biolabs says, "and such achievements underscore the potential of ADCs to fight against many cancers beyond breast cancer, energizing the ADC community to push boundaries even further. The World ADC Summit offers an ideal platform for us to showcase how our services align with this momentum, propelling ADCs into frontline therapies that improve patient lives."
Creative Biolabs, particularly known for ADC discovery and development capabilities, supports every stage of ADC development from early discovery through clinical manufacturing, including antibody engineering, linker design, and payload selection.
A core strength lies in its bioconjugation chemistry services—Creative Biolabs has mastered the art to offer expert antibody design and antibody-linker conjugations utilizing both site-specific and random conjugation methods, thus enabling the precise control over the attachment of cytotoxic drugs to antibodies and supporting clients in achieving the ideal balance between safety and efficacy for each therapeutic application.
"Designing a chemically compatible antibody for the conjugation chemistry is a key step intuitively dictating the fate of an ADC project. We've prepared engineered/non-engineered antibodies that are conjugated to the corresponding drug-linker set in DrugLnk, purified via suitable liquid chromatography techniques, and of course characterized for some basic biochemical parameters such as drug-to-antibody ratio, stability, and conjugation site distribution, to expedite your project with clear objectives." The scientist explains.
Further enhancing ADC functionality are specialized linker and payload solutions that Creative Biolabs tailors to fit the unique requirements of each ADC project. Linkers—responsible for releasing the drug payload only at the targeted cancer site—are available in cleavable and non-cleavable forms, providing flexibility based on therapeutic needs. The company's extensive catalog of payloads includes a range of cytotoxic agents, ensuring targeted destruction of cancer cells while minimizing side effects on healthy tissue.
Creative Biolabs extends a warm invitation to all World ADC attendees to visit Booth #313 to learn more about its ADC solutions and discuss potential collaborations. The Creative Biolabs team looks forward to meeting with industry experts, sharing insights, and advancing the conversation on ADCs' role in oncology and beyond.
Website: https://www.creative-biolabs.com/adc
About
The World ADC Summit is the beginning of a busy quarter for Creative Biolabs in 2024, which is set to appear at the Scientist Solution Vendor Event - NIH 37 and Antibody Engineering & Therapeutics (US) 2024 in December. These events present valuable opportunities to connect with global experts and forge partnerships that accelerate ADC breakthroughs.
Media Contact
Company Name: Creative Biolabs
Contact Person: Candy Swift
Email: Send Email
Phone: 1-631-830-6441
Country: United States
Website: https://www.creative-biolabs.com/adc
